News and features

Members of the ICR’s Discovery Club were given an exclusive insight into how researchers sample, process and analyse tumour cells in the lab, as part of the ICR’s first virtual event for our donors.

A first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men in the UK.

Patients with metastatic breast cancer carrying a particular mutation fare better on one form of hormone therapy than another and can be identified using a blood test, according to a new study.

A new study shows how a crucial protein, which acts as trigger for cell division, helps release another key protein from the cell’s ‘control centre’.

A new drug that has passed safety tests in adults shows the potential to be effective against the aggressive childhood cancer neuroblastoma, scientists have found.

An aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently used in the treatment of colon and ovarian cancer, a study led by researchers at The Institute of Cancer Research, London, suggests.

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.

Monte Rosa Therapeutics, a company originally formed as a spinout from Cancer Research UK-funded drug discovery research at the ICR, in collaboration with Versant’s drug discovery engine Ridgeline Therapeutics, has closed a $96m ‘series B’ financing from investors to support the further development of its drug pipeline.

Lara Jukes is the Director of Development at the ICR. Here she shares her personal thoughts on the impact the coronavirus pandemic has had on the charity, the life-saving research it supports, and those who benefit from it.

Researchers at the ICR are working hard to improve the outlook for children with cancer. Here we look back on a decade of discoveries made possible by the support of the parent-led charity Christopher’s Smile, which was founded just over 10 years ago.

An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of prostate cancers which have become ‘addicted’ to growth signals, a major phase III clinical trial has shown.

A new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who are at a high risk of recurrence has been shown to reduce the risk by 25 per cent in the first two years, according to a new study.